Mr. Wittenberg’s practice focuses primarily on biotechnology, medtech and healthcare IT companies. His recent representations include:
- Acetylon Pharmaceuticals, Inc. in its collaborative agreement with Celgene Corporation providing for $100 million in non-dilutive development financing and a buyout option of up to $1.7 billion
- athenahealth, Inc, a provider of cloud-based electronic health records, practice management and care coordination services to doctors and hospitals, in its $293 million acquisition of Epocrates, Inc., a developer and provider of one of the most widely-used clinical information tools for healthcare professionals
- Action Pharma, in the $110 million sale of the rights to develop and commercialize the kidney drug compound AP214 to Abbott Laboratories
- Abide Therapeutics, Inc., in its $430 million collaboration with Merck in the metabolic disease and diabetes fields
- Abide Therapeutics in its collaborative agreement with Celgene Corporation
- Akashi Therapeutics in its $100 million partnership with Gruenthal Group
- Patient Ping in its $31 million Series B financing
- QPID Health in its sale to eviCore healthcare
- Vascular Biogenics in its $15 million follow-on public offering
- C4 Therapeutics (C4) in its launch from Dana-Farber Cancer Institute, $73 million Series A financing and strategic collaboration with Roche
- Vividion Therapeutics in its $50 million Series A financing
- Acetylon Pharmaceuticals in its spin-out of Regenacy Pharmaceuticals and sale to Celgene Corporation
Mr. Wittenberg serves on the board of directors of MassBio, an association of more than 600 biotechnology companies, universities, academic institutions and others dedicated to advancing cutting edge research.
Prior to joining Goodwin, Mr. Wittenberg was a partner in the Business Practice Group at Testa, Hurwitz & Thibeault, where he co-founded and headed its Life Sciences Practice.